Cepheid Posts 16-Percent Rise in Q3 Sales as Losses Swell 18 Percent | GenomeWeb
This update includes the fact that Cepheid ended the quarter with $82.2 million in marketable securities as well as $16.2 million in cash and equivalents.
 
NEW YORK (GenomeWeb News) — Cepheid today said third-quarter revenues increased 16 percent as R&D spending rose 17 percent and net loss increased 18 percent.
 
Total receipts for the three months ended Sept. 30 increased to $23.8 million from $20.4 million year over year.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Biology this week: comparative genomics study of Aspergillus, genetic variation in indigenous African cattle, and more.

Some people who harbor genetic variants associated with disease show no signs and may give insight into the continuum of symptoms, Spectrum reports.

Some 57 snow monkeys at a Japanese zoo were found to be rhesus macaque hybrids, which are banned in Japan.

British researchers say they've been removed from EU grant applications, according to the Guardian.